The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A possible mechanism of antibody-dependent cellular cytotoxicity (ADCC) of lymphokine-activated killer cells (LAK) with cetuximab for the treatment of mutated KRAS or BRAF metastatic colorectal cancer (mCRC).
Y. Inoue
No relevant relationships to disclose
S. Hazama
No relevant relationships to disclose
M. Irie
No relevant relationships to disclose
Y. Shindo
No relevant relationships to disclose
Y. Maeda
No relevant relationships to disclose
N. Suzuki
No relevant relationships to disclose
K. Yoshimura
No relevant relationships to disclose
S. Yoshino
No relevant relationships to disclose
M. Oka
No relevant relationships to disclose